Who are Vivitrol (Medication Therapy)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Symproic, Movantik, Entereg, Relistor, Revex, Narcan.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/vivitrol-medication-therapy.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Vivitrol (Medication Therapy) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Vivitrol (Medication Therapy) (Vivitrol (Medication Therapy)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Opioid antagonist. Area: Psychiatry / Addiction Medicine.

marketed Opioid antagonist Opioid receptors (mu, delta, kappa) Psychiatry / Addiction Medicine Small molecule Live · refreshed every 30 min

Target snapshot

Vivitrol (Medication Therapy) (Vivitrol (Medication Therapy)) — Pacific Institute for Research and Evaluation. Vivitrol is a long-acting opioid antagonist that blocks opioid receptors to prevent euphoria and reduce cravings in opioid and alcohol use disorders.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Vivitrol (Medication Therapy) TARGET	Vivitrol (Medication Therapy)	Pacific Institute for Research and Evaluation	marketed	Opioid antagonist	Opioid receptors (mu, delta, kappa)
Symproic	NALDEMEDINE	Bdsi	marketed	Opioid Antagonist	Mu-type opioid receptor	2017-01-01
Movantik	NALOXEGOL	Averitas	marketed	Opioid Antagonist	Mu-type opioid receptor	2014-01-01
Entereg	ALVIMOPAN	Cubist Pharms	marketed	Opioid Antagonist	µ-opioid receptor	2008-01-01
Relistor	METHYLNALTREXONE	Salix Pharms	marketed	Opioid Antagonist	Mu-type opioid receptor	2008-01-01
Revex	NALMEFENE	Hikma	marketed	Opioid Antagonist	Kappa-type opioid receptor	1995-01-01
Narcan	NALOXONE	Adapt	marketed	Opioid Antagonist	Mu-type opioid receptor	1971-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Opioid antagonist class)

Norwegian University of Science and Technology · 2 drugs in this class
Green Cross Corporation · 1 drug in this class
Middle Tennessee Research Institute · 1 drug in this class
Develco Pharma Schweiz AG · 1 drug in this class
Pacific Institute for Research and Evaluation · 1 drug in this class
Pfizer · 1 drug in this class
NYU Langone Health · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Vivitrol (Medication Therapy) — Competitive Intelligence Brief. https://druglandscape.com/ci/vivitrol-medication-therapy. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab